Company intelligence / Profile preview

Talaris Therapeutics

Louisville, Kentucky, United Statesleadiq.com ↗

Ownership: Private
Employees: ~100
Development stage: Phase 3

Overview

Talaris discontinued FREEDOM-1 and FREEDOM-2 clinical trials for kidney transplant recipients in February 2023 due to slow enrollment. The company merged with Tourmaline Bio in October 2023, shifting focus to TOUR006, an anti-IL-6 antibody for thyroid eye disease and atherosclerotic cardiovascular disease.

Therapeutic areas: ImmunologyCardiovascularEndocrinologyRheumatology
Modalities: Cell therapyallogeneic cell therapy
Industry: Biotech

Drug pipeline

1 asset

Talaris-201

Phase 2

Indications: Solid organ transplantation

Beyond the preview

Go deeper on Talaris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talaris Therapeutics.

Explore the full profile